EMH
0.38
76.7%
C7A
0.002
-50%
DTM
0.055
66.7%
BOC
0.6
-47.8%
SRL
6.62
56.5%
TR2
0.395
-35.2%
CLE
0.065
54.8%
1TT
0.002
-33.3%
CBE
0.15
53.1%
BLZ
0.002
-33.3%
BIT
0.003
50%
LNU
0.002
-33.3%
EXR
0.063
50%
M2M
0.012
-29.4%
M2R
0.003
50%
MGU
0.005
-28.6%
TGN
0.225
50%
EZZ
1.7
-28.1%
MTM
1.02
48.9%
VMM
0.98
-26.9%
TNC
0.605
47.6%
PGY
0.003
-25%
AUR
0.023
43.8%
KOB
0.055
-23.6%
SRJ
0.017
41.7%
FMR
0.26
-21.2%
ZNC
0.115
40.2%
BOA
0.027
-20.6%
AEU
0.335
39.6%
AUG
0.035
-20.5%
EQR
0.064
39.1%
OEL
0.004
-20%
SKM
0.285
39%
VEN
0.004
-20%
DGR
0.025
38.9%
OCT
0.037
-19.6%
HIQ
0.025
38.9%
L1M
0.031
-18.4%
PTX
0.074
37%
DKM
0.14
-17.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EZZ Life Science (ASX: EZZ): Targets US expansion followingFDA product approvals

Australian genomic life science company EZZ Life Science (ASX: EZZ) has won approval from the United States (US) Food and Drug Administration (FDA) for nine of its products in the food category, presenting a significant US expansion opportunity for EZZ. | ASX announcement: https://announcements.asx.com.au/asxpdf/20240625/pdf/064x2fh3lh72px.pdf